{"@context": {"rdfs": "http://www.w3.org/2000/01/rdf-schema#", "xsd": "http://www.w3.org/2001/XMLSchema#", "pav": "http://purl.org/pav/", "schema": "http://schema.org/", "oslc": "http://open-services.net/ns/core#", "rdfs:label": {"@type": "xsd:string"}, "schema:isBasedOn": {"@type": "@id"}, "schema:name": {"@type": "xsd:string"}, "schema:description": {"@type": "xsd:string"}, "pav:createdOn": {"@type": "xsd:dateTime"}, "pav:createdBy": {"@type": "@id"}, "pav:lastUpdatedOn": {"@type": "xsd:dateTime"}, "oslc:modifiedBy": {"@type": "@id"}, "BioProject for AIRR NCBI": "https://schema.staging.metadatacenter.org/properties/84d77774-b685-462e-a6b3-b47fea8b21cf", "Sequence Read Archive for AIRR NCBI": "https://schema.staging.metadatacenter.org/properties/49815922-ead0-42c4-88f1-0ddf1d4d4c9e", "BioSample for AIRR NCBI": "https://schema.staging.metadatacenter.org/properties/55996c02-1636-41ba-bf10-f5aaf3733708"}, "BioProject for AIRR NCBI": {"@context": {"Study Criteria": "http://scdontology.h3abionet.org/ontology/SCDO_0001033", "Study ID": "http://semantic-dicom.org/dcm#StudyID", "Funding Agency": "http://purl.org/net/OCRe/OCRe.owl#OCRE850077", "Lab Name": "http://www.w3.org/2000/01/rdf-schema#label", "Study Title": "http://purl.org/dc/elements/1.1/title", "Study Type": "http://purl.org/dc/elements/1.1/type", "Relevant Publications": "http://xmlns.com/foaf/0.1/publications", "Lab Address": "https://schema.staging.metadatacenter.net/properties/25427e1c-7d44-4d93-b7f9-913c28e91333", "Contact Information (data collection)": "https://schema.staging.metadatacenter.org/properties/d4210479-a917-4af6-aee4-c51ee39ec8fd"}, "Study Criteria": {"@value": "MS patients were recruited at the Revalidation & MS Center (Overpelt, Belgium) and were diagnosed according to the McDonald criteria. HC were recruited at the Biomedical Research Institute (Diepenbeek, Belgium)."}, "Study ID": {"@value": "PRJNA429427"}, "Funding Agency": {"@value": "This work was supported by the National Multiple Sclerosis Society (PP-1509-06370), the Belgian Charcot Foundation and the National Institutes of Health (NIH) (R01AI104739)."}, "Lab Name": {"@value": "Kleinstein Lab, Oconnor Lab, Sommers Lab"}, "Study Title": {"@value": "DN B cells in Multiple Sclerosis (MS) patients and healthy controls (HC)"}, "Study Type": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "Relevant Publications": {"@value": null}, "Lab Address": {"@value": "Department of Pathology"}, "Contact Information (data collection)": {"@value": "steven.kleinstein@yale.edu"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/c491fef9-cff9-4147-a329-bc3c073ee60a"}, "Sequence Read Archive for AIRR NCBI": [{"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA\n"}, "Date of Sequencing Run": {"@value": "05/03/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=6.3"}, "Forward PCR Primer Target Location": {"@value": "NA\n"}, "Reverse PCR Primer Target Location": {"@value": "NA\n"}, "Batch Number": {"@value": "AP626"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA\n"}, "Physical Linkage of Different Loci": {"@value": "NA\n"}, "Sample ID": {"@value": "MS537_M_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq1_001_ATCACG_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq1_001_ATCACG_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "05/03/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=4.5"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP626"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "MS537_DN_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq2_002_CGATGT_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq2_002_CGATGT_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "05/03/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=4.5"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP626"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "HC038_M_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq7_007_CAGATC_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq7_007_CAGATC_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "05/03/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=5.2"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP626"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "HC038_DN_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq8_008_ACTTGA_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq8_008_ACTTGA_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=4.6"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "HC024_M_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_001_ATCACG_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_001_ATCACG_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=5.8"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "HC024_DN_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_002_CGATGT_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_002_CGATGT_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=7.2"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "HC263_M_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_003_TTAGGC_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_003_TTAGGC_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=3.2"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "HC263_DN_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_004_TGACCA_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_004_TGACCA_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=5.7"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "MS560_M_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_005_ACAGTG_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_005_ACAGTG_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=5.1"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "MS560_DN_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_006_GCCAAT_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_006_GCCAAT_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=6"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "MS085_M_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_007_CAGATC_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_007_CAGATC_L001_R2_001_convert-pass_nophix.fastq"}}, {"@context": {"Read Lengths": "https://schema.staging.metadatacenter.net/properties/readLength", "Template Amount": "https://schema.staging.metadatacenter.net/properties/nGTemplate", "Target Locus for PCR": "https://schema.staging.metadatacenter.net/properties/targetLocusPCR", "Date of Sequencing Run": "https://schema.staging.metadatacenter.org/properties/7e1a52f9-6782-47bb-bb04-23ca22576da2", "File Type": "https://schema.staging.metadatacenter.org/properties/0cfb3ace-ddd3-4e7d-87ed-4dc33eb21c80", "Sequencing Platform": "https://schema.staging.metadatacenter.net/properties/sequencingPlatform", "Sequencing Facility": "https://schema.staging.metadatacenter.net/properties/sequencingFacility", "Library Generation Protocol": "https://schema.staging.metadatacenter.net/properties/libraryGenerationProtocol", "Target Substrate Quality": "https://schema.staging.metadatacenter.net/properties/targetSubstrateQuality", "Forward PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/forwardPCRPrimerTargetLocation", "Reverse PCR Primer Target Location": "https://schema.staging.metadatacenter.net/properties/reversePCRPrimerTargetLocation", "Batch Number": "https://schema.staging.metadatacenter.net/properties/batchNumber", "Total Reads Passing QC Filter": "https://schema.staging.metadatacenter.net/properties/totalReadsPassingQCFilter", "Sequencing Kit": "https://schema.staging.metadatacenter.net/properties/sequencingKit", "Target Substrate": "https://schema.staging.metadatacenter.org/properties/06f0942e-dd2a-40b4-8654-e19ccf18e362", "Library Generation Method": "https://schema.staging.metadatacenter.org/properties/53a17c41-2350-4b4a-9cd7-9d83ed2f2479", "Protocol IDs": "https://schema.staging.metadatacenter.net/properties/protocolID", "Complete Sequences": "https://schema.staging.metadatacenter.org/properties/c2cc02a0-285f-42ee-b978-3c7c97fe1409", "Physical Linkage of Different Loci": "https://schema.staging.metadatacenter.org/properties/a86df8b6-a6fb-4f59-9c24-c84b980eae2f", "Sample ID": "https://schema.staging.metadatacenter.org/properties/a9245679-8b2f-4c49-8783-b3a321b47e45", "Nucleic Acid Processing ID": "https://schema.staging.metadatacenter.org/properties/e3457b17-8b51-4924-89c8-d00d4f32a92e"}, "Read Lengths": {"@value": "Read 1 326, Read 2 276"}, "Template Amount": {"@value": "NA"}, "Target Locus for PCR": {"@value": "NA"}, "Date of Sequencing Run": {"@value": "09/16/2016", "@type": "xsd:date"}, "File Type": {"@value": "sra-run-fastq"}, "Sequencing Platform": {"@value": "Illumina MiSeq"}, "Sequencing Facility": {"@value": "W.M. Keck Biotechnology Resource Laboratory (Yale University)"}, "Library Generation Protocol": {"@value": "Total RNA was extracted from the sorted cells with RNAeasy kit (QIAGEN) according to the manufacturer\u2019s protocol. Amplicons for sequencing on the Illumina MiSEQ platform were synthesized using commercial reagents and a protocol provided by the manufacturer (New England Biolabs, Ipswich MA). Briefly, extracted RNA (100 ng) was reverse-transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was added to the 3\u2019 end of all cDNA, which contains a universal priming site and a 17-nucleotide unique molecular identifier (UMI). Products were purified using streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC, and IGLC regions, as well as a primer against the universal adapter sequence. The Ig-specific primers contained tail sequences for the later Illumina adapter addition. PCR products were then purified using AMPure XP beads. A secondary PCR was then performed to add the Illumina P5 adapter to the C region end and a sample-indexed P7 adapter to the universal adapter end. The number of secondary PCR cycles was tailored to each sample to avoid entering the plateau phase, as judged by a prior quantitative PCR analysis. Final products were purified, then quantified with a TapeStation (Agilent Genomics)."}, "Target Substrate Quality": {"@value": "RIN=4.6"}, "Forward PCR Primer Target Location": {"@value": "NA"}, "Reverse PCR Primer Target Location": {"@value": "NA"}, "Batch Number": {"@value": "AP4AC"}, "Total Reads Passing QC Filter": {"@value": "NA"}, "Sequencing Kit": {"@value": "New England Biolabs"}, "filename": ["filename1", "filename2"], "Target Substrate": {"@value": "RNA"}, "Library Generation Method": {"@value": "amplicon"}, "Protocol IDs": {"@value": "New England Biolabs, Ipswich MA"}, "Complete Sequences": {"@value": "NA"}, "Physical Linkage of Different Loci": {"@value": "NA"}, "Sample ID": {"@value": "MS085_DN_842096579"}, "Nucleic Acid Processing ID": {"@value": "NA"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/8386627f-270c-4171-938c-1f8748328ea3", "filename1": {"@value": "KCO_Seq_2_008_ACTTGA_L001_R1_001_convert-pass_nophix.fastq"}, "filename2": {"@value": "KCO_Seq_2_008_ACTTGA_L001_R2_001_convert-pass_nophix.fastq"}}], "BioSample for AIRR NCBI": [{"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "41"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "< 1 y"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "None"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": " IgD-CD27+ B cells from subject with relapsing-remitting multiple sclerosis"}, "Cell Subset Phenotype": {"@value": "IgD-CD27+"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "EDSS=4.5"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "433266"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "EDSS=4.5"}, "Sample ID": {"@value": "MS537_M_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "MS537"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": ""}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "41"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "< 1 y"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "None"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": "DN B cells from subject with relapsing-remitting multiple sclerosis"}, "Cell Subset Phenotype": {"@value": "DN"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "EDSS=4.5"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "30025"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "EDSS=4.5"}, "Sample ID": {"@value": "MS537_DN_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "MS537"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": ""}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "24"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "NA"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "NA"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": " IgD-CD27+ B cells from control subject"}, "Cell Subset Phenotype": {"@value": "IgD-CD27+"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "NA"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "154643"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "NA"}, "Sample ID": {"@value": "HC038_M_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "HC038"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "24"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "NA"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "NA"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": "DN B cells from control subject"}, "Cell Subset Phenotype": {"@value": "DN"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "NA"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "51517"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "NA"}, "Sample ID": {"@value": "HC038_DN_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "HC038"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "54"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "NA"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "NA"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": " IgD-CD27+ B cells from control subject"}, "Cell Subset Phenotype": {"@value": "IgD-CD27+"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "NA"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "238000"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "NA"}, "Sample ID": {"@value": "HC024_M_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "HC024"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "54"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "NA"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "NA"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": "DN B cells from control subject"}, "Cell Subset Phenotype": {"@value": "DN"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "NA"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "33600"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "NA"}, "Sample ID": {"@value": "HC024_DN_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "HC024"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "39"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "NA"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "NA"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": " IgD-CD27+ B cells from control subject"}, "Cell Subset Phenotype": {"@value": "IgD-CD27+"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "NA"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "370125"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "NA"}, "Sample ID": {"@value": "HC263_M_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "HC263"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "39"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "NA"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "NA"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": "DN B cells from control subject"}, "Cell Subset Phenotype": {"@value": "DN"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "NA"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "42304"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "NA"}, "Sample ID": {"@value": "HC263_DN_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "HC263"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "23"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "1.5 y"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "None"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": " IgD-CD27+ B cells from subject with relapsing-remitting multiple sclerosis"}, "Cell Subset Phenotype": {"@value": "IgD-CD27+"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "EDSS=6"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "747620"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "EDSS=6"}, "Sample ID": {"@value": "MS560_M_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "MS560"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "23"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "1.5 y"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "None"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": "DN B cells from subject with relapsing-remitting multiple sclerosis"}, "Cell Subset Phenotype": {"@value": "DN"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "EDSS=6"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "111100"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "EDSS=6"}, "Sample ID": {"@value": "MS560_DN_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "MS560"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "49"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "23 y"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "None"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": " IgD-CD27+ B cells from subject with relapsing-remitting multiple sclerosis"}, "Cell Subset Phenotype": {"@value": "IgD-CD27+"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "EDSS=5"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "196358"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "EDSS=5"}, "Sample ID": {"@value": "MS085_M_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "MS085"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}, {"@context": {"Age": "http://xmlns.com/foaf/0.1/age", "Biomaterial Provider": "https://schema.staging.metadatacenter.net/properties/biomaterialProvider", "Cell Quality": "https://schema.staging.metadatacenter.net/properties/cellQuality", "Sex": "http://www.loria.fr/~coulet/sopharm/SOPHARM_05103", "Age Event": "https://schema.staging.metadatacenter.net/properties/ageEvent", "Cell Subset": "https://schema.staging.metadatacenter.net/properties/cellType", "Cell Isolation": "https://schema.staging.metadatacenter.net/properties/cellIsolation", "Ethnicity": "https://schema.staging.metadatacenter.net/properties/ethnicity", "Length of Disease": "https://schema.staging.metadatacenter.net/properties/diseaseLength", "Tissue": "http://chem2bio2rdf.org/chem2bio2rdf.owl#tissue", "Tissue Processing": "https://schema.staging.metadatacenter.net/properties/tissueProcessing", "Sample Type": "https://schema.staging.metadatacenter.net/properties/bioSample", "Other Relevant Medical History": "https://schema.staging.metadatacenter.net/properties/medicalHistory", "Organism": "http://chem2bio2rdf.org/chem2bio2rdf.owl#organism", "Anatomic Site": "https://schema.staging.metadatacenter.net/properties/anatomicSite", "Race": "https://schema.staging.metadatacenter.net/properties/race", "Prior Therapies for Primary Disease under Study": "https://schema.staging.metadatacenter.net/properties/priorTherapies", "Intervention Definition": "https://schema.staging.metadatacenter.net/properties/interventionDefinition", "Ancestry Population": "https://schema.staging.metadatacenter.net/properties/ancestryPopulation", "Study Group Description": "https://schema.staging.metadatacenter.net/properties/studyGroupDescription", "Cell Subset Phenotype": "https://schema.staging.metadatacenter.net/properties/phenotype", "Immunogen": "https://schema.staging.metadatacenter.net/properties/immunogen", "Relation Type": "https://schema.staging.metadatacenter.net/properties/linkType", "Projected Release Date": "https://schema.staging.metadatacenter.net/properties/a9e4fd79-df27-4322-93b7-e1d7a017d978", "Disease State of Sample": "https://schema.staging.metadatacenter.net/properties/diseaseStateSample", "Number of Cells per Sequencing Reaction": "https://schema.staging.metadatacenter.net/properties/cellNumber", "Number of Cells in Experiment": "https://schema.staging.metadatacenter.net/properties/cellSubtype", "Sample Collection Time": "https://schema.staging.metadatacenter.org/properties/e7aef499-af43-4168-9a27-972b64faff72", "Single-cell Sort": "https://schema.staging.metadatacenter.org/properties/2aed928b-0759-414f-a79d-e54768c099bd", "Cell Storage": "https://schema.staging.metadatacenter.org/properties/cf694d08-4aaf-45e5-badc-d12f17991b40", "Strain Name": "https://schema.staging.metadatacenter.net/properties/starinName", "Related Subjects": "https://schema.staging.metadatacenter.net/properties/subjectLinked", "Disease Stage": "https://schema.staging.metadatacenter.net/properties/diseaseStage", "Sample ID": "http://www.geneontology.org/formats/oboInOwl#id", "Collection Time Event": "https://schema.staging.metadatacenter.net/properties/collectionTimeEvent", "Subject ID": "https://schema.staging.metadatacenter.net/properties/24f93b6d-8578-46db-a73a-b31b164ce8f4", "Synthetic Library": "https://schema.staging.metadatacenter.org/properties/66383cde-b8a7-4843-8c19-91a1face7f38", "Cell Processing Protocol": "https://schema.staging.metadatacenter.net/properties/processingProtocol", "Diagnosis1": "https://schema.staging.metadatacenter.net/properties/f80c31ca-9b63-4a16-8efa-4d98a42613f7"}, "Age": {"@value": "49"}, "Biomaterial Provider": {"@value": "Veerle Somers (Hasselt University) and Kevin O'Connor (Yale University)"}, "Cell Quality": {"@value": "NA"}, "Sex": {"@id": "http://purl.bioontology.org/ontology/SNOMEDCT/248152002", "rdfs:label": "Female"}, "Age Event": {"@value": "NA"}, "Cell Subset": {"@id": "http://purl.obolibrary.org/obo/CL_0000236", "rdfs:label": "B cell"}, "Cell Isolation": {"@value": "Flow cytometry"}, "Ethnicity": {"@value": "NA"}, "Length of Disease": {"@value": "23 y"}, "Tissue": {"@id": "http://purl.obolibrary.org/obo/BTO_0000089", "rdfs:label": "blood"}, "Tissue Processing": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Sample Type": {"@value": "peripheral venous puncture"}, "Other Relevant Medical History": {"@value": "NA"}, "Organism": {"@type": "http://data.bioontology.org/ontologies/NCIT/classes/http%3A%2F%2Fncicb.nci.nih.gov%2Fxml%2Fowl%2FEVS%2FThesaurus.owl%23C70713", "@id": "http://purl.bioontology.org/ontology/NCBITAXON/9606", "rdfs:label": "Homo sapiens"}, "Anatomic Site": {"@value": "NA"}, "Race": {"@value": "NA"}, "Prior Therapies for Primary Disease under Study": {"@value": "None"}, "Intervention Definition": {"@value": "None"}, "Ancestry Population": {"@value": "NA"}, "Study Group Description": {"@value": "DN B cells from subject with relapsing-remitting multiple sclerosis"}, "Cell Subset Phenotype": {"@value": "DN"}, "Immunogen": {"@value": "None"}, "Optional BioSample Attribute": ["Optional Attribute1"], "Relation Type": {"@value": "NA"}, "Projected Release Date": {"@value": "01/22/2020", "@type": "xsd:date"}, "Disease State of Sample": {"@value": "EDSS=5"}, "Number of Cells per Sequencing Reaction": {"@value": "NA"}, "Number of Cells in Experiment": {"@value": "20553"}, "Sample Collection Time": {"@value": "NA"}, "Single-cell Sort": {"@value": null}, "Cell Storage": {"@value": null}, "Strain Name": {"@value": "NA"}, "Related Subjects": {"@value": "NA"}, "Disease Stage": {"@value": "EDSS=5"}, "Sample ID": {"@value": "MS085_DN_842096579"}, "Collection Time Event": {"@value": "NA"}, "Subject ID": {"@value": "MS085"}, "Synthetic Library": {"@value": null}, "Cell Processing Protocol": {"@value": "PBMC were isolated from whole blood by Ficoll density gradient centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, The Netherlands). B cells were purified from the PBMC using negative magnetic selection (STEMCELL Technologies SARL, Grenoble, France) according to the manufacturer\u2019s instructions. Purity of the isolated B cells was routinely \u2265 99.5% as determined by flow cytometry on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium) following the staining described below. For the isolation of DN and IgD-CD27+ memory B cells, the enriched B cells were stained with anti-human CD27 allophycocyanin (APC, clone M-T271), IgD PE-CF594 (clone IA6-2) (both from BD Biosciences) and CD19 PE-Cy7 (clone HIB19; BioLegend, ImTec Diagnostics, Antwerp, Belgium) during 30 min at 4\u00b0C. At least 2 x 104 DN (IgD-CD27-) or class-switched memory (IgD-CD27+) B cells were then sorted on a FACSAria II flow cytometer (BD Biosciences) using single-color gating controls. Sorted cells were pelleted or suspended in RNAlater\u00ae Stabilization Solution (ThermoFisher Scientific, Erembodegem, Belgium) before storage at -80\u00b0C."}, "Diagnosis1": {"@id": "http://data.bioontology.org/provisional_classes/732bcd70-3457-0136-3944-005056010073", "rdfs:label": "not available"}, "@id": "https://repo.staging.metadatacenter.org/template-element-instances/2d0d9864-c9e9-4bfb-b309-c35ee959d0c4", "Optional Attribute1": {"@value": null}}], "schema:isBasedOn": "https://repo.staging.metadatacenter.org/templates/173c7641-e6fb-4433-9ad8-f516849d46e8", "schema:name": "MiAIRR RC2 v2 metadata", "schema:description": "Enables AIRR-seq data submission to the NCBI through the CEDAR Workbench"}